Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoma
Open-data reference.
30 US clinical trials · 10 currently recruiting
Active & Recent Trials
Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer
Roswell Park Cancer Institute
NCT06456411
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Marengo Therapeutics
NCT05592626
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
AstraZeneca
NCT05261399
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18
NCT04787042
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Travera
NCT05461430
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Alain Algazi
NCT03708224
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Zachary Zumsteg
NCT06445114
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
NCT05559879
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NATCO Pharma
NCT05283226
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Roberto Vargas
NCT05065736
Exercise Exposure Data Collection in Patients Undergoing Tumor Molecular Profiling
Memorial Sloan Kettering Cancer Center
NCT03208374
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
AstraZeneca
NCT03778229
Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer
Alliance for Clinical Trials in Oncology
NCT03857620
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT04483778
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
NCT03091192
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
NCT03618381
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Washington University School of Medicine
NCT01061515
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
VA Office of Research and Development
NCT00847912
Early Diagnosis of Pulmonary Nodules
Integrated Diagnostics
NCT01752114
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Amgen
NCT00838201
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis Pharmaceuticals
NCT00719264
Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings
UNC Lineberger Comprehensive Cancer Center
NCT04931251
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin
NCT02705105
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
NCT00770536
Smartphone App for Cancer Medication Adherence
Columbia University
NCT05225090
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
Xoft
NCT00742222
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
TaiRx
NCT02507544
A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma
Spectrum Pharmaceuticals
NCT00613691
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
NCT01916135
Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases
Anza Therapeutics
NCT00327652
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 13 |
| Phase 2 | 5 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Carcinoma Trial Landscape
ClinicalTrials.gov lists 30 US studies indexed under Carcinoma, and 10 of those are currently open to recruitment — roughly 33% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Carcinoma shows 5 late-stage studies (Phase 3 and Phase 4 combined) alongside 18 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Carcinoma is led by AstraZeneca with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 30 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Carcinoma?
PlainTrial tracks 30 US clinical trials for Carcinoma, of which 10 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Carcinoma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.